title: Gangliosides inhibit growth factor-stimulated neurite outgrowth in SH-SY5Y human neuroblastoma cells.
abstract: Exogenously added gangliosides are known to promote neurite outgrowth in a variety of cell types, including some neuroblastoma cell lines. To study neuritogenesis in SH-SY5Y human neuroblastoma we serum starved the cells for 24 hr and exposed them to gangliosides (GM1, GM3, or GT1b), platelet-derived growth factor (PDGF), insulin, nerve growth factor (NGF), insulin-like growth factor I (IGF-I), or combinations of these for 3 days. We measured four parameters of neurite outgrowth using image analysis. PDGF induced neurite outgrowth in SH-SY5Y and GM1 inhibited this. Both phenomena were dose-dependent with neurites/cell and neurite length being below controls with 100 microM GM1, and percent of neurite-bearing cells being below controls with 25, 50, and 100 microM GM1. Similar but more inhibitory results were obtained with GM3 and GT1b. Insulin and IGF-I induced a neuritogenic response that was less potent than that of PDGF and was also inhibited by gangliosides. NGF had no effect on neurite outgrowth but gangliosides were still inhibitory even in cells not treated with growth factors. From this we conclude that gangliosides inhibit spontaneous and trophic factor-induced neurite outgrowth in SH-SY5Y cells. For GM1 and GT1b, but not GM3, this probably involves inhibition of trophic factor receptor function.
authors.affiliation: Department of Pathology, Ohio State University, Columbus, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Hynds
authors.forename: R W
authors.initials: RW
authors.lastname: Burry
authors.forename: A J
authors.initials: AJ
authors.lastname: Yates
mesh_terms: D016895:Culture Media, Serum-Free; D004305:Dose-Response Relationship, Drug; D005677:G(M1) Ganglioside / Q000494:pharmacology; D005679:G(M3) Ganglioside / Q000494:pharmacology; D005732:Gangliosides / Q000494:pharmacology*; D006131:Growth Inhibitors; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007700:Kinetics; D009414:Nerve Growth Factors / Q000494:pharmacology; D016501:Neurites / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D009447:Neuroblastoma; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D016895:Culture Media, Serum-Free; D005679:G(M3) Ganglioside; D005732:Gangliosides; D006131:Growth Inhibitors; D006133:Growth Substances; D007328:Insulin; D009414:Nerve Growth Factors; D010982:Platelet-Derived Growth Factor; D005677:G(M1) Ganglioside; C016481:trisialoganglioside GT1; D007334:Insulin-Like Growth Factor I